Electroconvulsive Therapy Is an Essential Procedure
Publication: American Journal of Psychiatry
The COVID-19 pandemic is dramatically affecting mental health and the treatment of psychiatric illness. Isolation and stress are associated with worsening symptoms, substance abuse, and suicidality (1). For those with the most severe forms of depression and other mental illnesses, electroconvulsive therapy (ECT) is a critical and often lifesaving treatment strategy, but with COVID-19, the administration of ECT has been markedly disrupted.
Because of the need for bag and mask ventilation during anesthesia, ECT for patients with highly infectious respiratory conditions poses a substantial risk to health care workers and other patients, given the potential for aerosolizing viral droplets. Early in the pandemic, the Centers for Medicare and Medicaid Services issued guidance focused on limiting nonemergent and elective medical care to conserve health care resources and reduce infection rates within a tiered acuity framework (2). Many health care institutions classified ECT as an elective procedure or were concerned about scarce personal protective equipment and anesthesiology resources, leading to a flurry of concerns from clinicians, patients, and families (3). These concerns led APA and the National Network of Depression Centers to publish position statements calling for the continued availability of ECT (4, 5).
To better understand the actual extent of the COVID-19 impact on patients and ECT practice in the United States, the ECT Task Group of the National Network of Depression Centers, a consortium of 27 U.S. academic institutions, surveyed members about the effects of COVID-19 on 20 ECT programs. During April and May of 2020, 80% (16 of 20) of ECT programs in the National Network of Depression Centers reported operating at less than 50% of regular clinical volume, and some reported substantially greater declines. ECT teams of psychiatrists and nurses scrambled to postpone or cancel appointments for many patients who were in acute or maintenance ECT courses. In addition, 95% of programs were required to delay or defer some new patients from starting ECT. Most importantly, our survey documented patient outcomes that were alarming: COVID-19 caused scheduling changes for ECT that led to decompensation and hospitalization (70% of institutions) or a need for new acute courses of ECT for patients whose maintenance ECT was stopped or curtailed (80% of institutions). There was one reported death by suicide, and 15% of sites reported at least one serious suicide attempt during ECT service reductions imposed by COVID-19. What may never be known are any untoward effects among any new patients who did not receive timely ECT consultations.
Fortunately, with reductions in COVID-19 infection rates during the late spring of 2020, along with the improved availability of personal protective equipment, COVID-19 testing protocols, and increasingly productive collaborations with anesthesiology and infection prevention teams, more than half of the 20 ECT programs in the National Network of Depression Centers were able to ramp up to at least 75% of a typical patient load by early June 2020. Our survey demonstrates that despite a worldwide pandemic, the most vulnerable patients can receive ECT care with sophisticated safety protocols developed by health care providers.
A resurgence of COVID-19 cases during the winter of 2020–2021 across the United States raised renewed concerns that the availability of ECT may again be affected, with disastrous implications for patients. Hospital administrators and medical leadership need to understand that ECT patients often fall into urgent and emergent categories and that disruption or deferral of ECT care increases risks of relapse, hospitalizations, and potential suicide in this vulnerable population. Thus, it is imperative that ECT continue to be considered an essential treatment when severe psychiatric illness is present, whether it is during this COVID-19 crisis or in any future pandemic.
References
1.
Czeisler MÉ, Lane RI, Petrosky E, et al : Mental health, substance use, and suicidal ideation during the COVID-19 pandemic: United States, June 24–30, 2020. MMWR Morb Mortal Wkly Rep 2020 ; 69 : 1049 – 1057
2.
Centers for Medicare and Medicaid Services (CMS): Non-emergent, elective medical services, and treatment recommendations. CMS, Baltimore, 2020 (https://www.cms.gov/files/document/cms-non-emergent-elective-medical-recommendations.pdf)
3.
Espinoza RT, Kellner CH, McCall WV : Electroconvulsive therapy during COVID-19: an essential medical procedure: maintaining service viability and accessibility. J ECT 2020 ; 36 : 78 – 79
4.
American Psychiatric Association (APA): Electroconvulsive therapy as an essential procedure. APA, Washington, DC, 2020 (https://www.psychiatry.org/psychiatrists/covid-19-coronavirus)
5.
National Network of Depression Centers (NNDC): NNDC urges medical officials to consider ECT an essential medical service. NNDC, Ann Arbor, Mich, 2020 (https://nndc.org/nndc-urges-medical-officials-to-consider-ect-an-essential-medical-service)
Information & Authors
Information
Published In
History
Accepted: 22 December 2020
Published in print: May 01, 2021
Published online: 12 May 2021
Keywords
Authors
Competing Interests
Dr. Maixner has received research support for the clinical study of ketamine in depression and travel expenses for research development from the National Network of Depression Centers, and he has received research funding from Neuronetics and St. Jude Medical. Dr. Reti has received grant support from the Brain and Behavior Research Foundation, the Dana Foundation, the U.S. Department of Defense, the Hope for Depression Research Foundation, NIH, the Patient-Centered Outcomes Research Institute, and the Simons Foundation for Autism Research Initiative, and he has had contracts with BrainsWay, John Wiley & Sons, and Neuronetics. Dr. Hermida has received grant support from the National Institute on Aging. Dr. Husain has received grant and/or research support from the BRAIN Initiative, NIMH, the National Institute on Aging, NIH, the National Institute of Neurological Disorders and Stroke, and the Stanley Foundation. Mr. Larsen serves as executive director of the National Network of Depression Centers. Dr. McDonald is a member of the APA Council on Research representing the practice of electroconvulsive and neuromodulation therapies; he receives compensation as chair of the data and safety monitoring board for the National Institute on Aging; he receives support from the Wounded Warrior Project as part of the Emory University Veterans Program; he receives royalties from Oxford University Press; he serves as a board member of Skyland Trail and 3Keys; he is a paid consultant for Signant Health and Parallel Georgia; and he has received funding from the J.B. Fuqua Foundation, Cervel Neurotherapeutics, Neuronetics, NeoSync, Soterix, and the Stanley Foundation. Dr. Weiner reports no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).